Sylvester Discusses Wave of Plaintiffs’ CBD-Level Lawsuits

07 October 2019 News

Special Counsel Brian Sylvester was quoted in the article, “Plaintiff’s Bar Turns Attention to CBD with Wave of Lawsuits Alleging Products Contain ‘Significantly Lower Levels’ Than Advertised,” about how the plaintiff’s bar has begun suing CBD product manufacturers over the level of CBD in their products. The suits claim that the CBD levels often are significantly lower than advertised on websites and labeling for the products.

Sylvester said the discrepancies were potentially a fertile ground for the plaintiff’s bar. “We’ve already heard from the FDA that as part of their regulatory enforcement activity (i.e., warning letters issues to firms that market unapproved new drugs that allegedly contain CBD), the FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. Plaintiffs have taken note of these findings.”

Related Services


2023 M&A Outlook
05 December 2022
Foley Ignite
COVID-related Form I-9 Remote Verification Flexibilities Extended Through July 31, 2023
05 December 2022
Labor & Employment Law Perspectives
Learnings from Recent Physician Practice Private Equity Transactions
05 December 2022
Health Care Law Today
Get up to Speed: Blockchain for the Auto Industry
05 December 2022
Dashboard Insights
What You Should Know About Payor/Provider Convergence
25-26 January 2023
Los Angeles, CA
ATA EDGE2022 Policy Conference | American Telemedicine Association
7-9 December 2022
Washington, D.C.
CLE Weeks
5-16 December 2022
Milwaukee, WI
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region